Olstein Capital Management L.P. continued to hold its stake in shares of Natus Medical Incorporated (NASDAQ:BABY) during the second quarter, Holdings Channel reports. The fund owned 86,845 shares of the medical equipment provider’s stock at the end of the second quarter. Olstein Capital Management L.P.’s holdings in Natus Medical were worth $3,239,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the company. Ameritas Investment Partners Inc. acquired a new stake in shares of Natus Medical during the first quarter worth about $110,000. Sei Investments Co. raised its stake in shares of Natus Medical by 29.7% in the second quarter. Sei Investments Co. now owns 3,182 shares of the medical equipment provider’s stock worth $119,000 after buying an additional 728 shares during the last quarter. Victory Capital Management Inc. raised its stake in shares of Natus Medical by 94.0% in the first quarter. Victory Capital Management Inc. now owns 3,184 shares of the medical equipment provider’s stock worth $125,000 after buying an additional 1,543 shares during the last quarter. State of Alaska Department of Revenue raised its stake in shares of Natus Medical by 1.7% in the first quarter. State of Alaska Department of Revenue now owns 3,630 shares of the medical equipment provider’s stock worth $142,000 after buying an additional 60 shares during the last quarter. Finally, Campbell & CO Investment Adviser LLC acquired a new stake in shares of Natus Medical during the second quarter worth about $204,000. 95.66% of the stock is currently owned by hedge funds and other institutional investors.

Natus Medical Incorporated (BABY) opened at 34.15 on Wednesday. The firm has a market capitalization of $1.11 billion, a price-to-earnings ratio of 59.19 and a beta of 0.93. Natus Medical Incorporated has a 1-year low of $32.83 and a 1-year high of $44.39. The stock has a 50 day moving average price of $36.35 and a 200 day moving average price of $36.60.

Natus Medical (NASDAQ:BABY) last issued its earnings results on Wednesday, July 26th. The medical equipment provider reported $0.34 EPS for the quarter, beating analysts’ consensus estimates of $0.33 by $0.01. Natus Medical had a return on equity of 12.09% and a net margin of 4.20%. The firm had revenue of $122.20 million for the quarter, compared to the consensus estimate of $121.99 million. During the same quarter in the previous year, the company posted $0.39 earnings per share. The business’s quarterly revenue was up 27.3% compared to the same quarter last year. Analysts predict that Natus Medical Incorporated will post $1.70 EPS for the current year.

WARNING: “Natus Medical Incorporated (BABY) Position Held by Olstein Capital Management L.P.” was posted by Watch List News and is the property of of Watch List News. If you are accessing this article on another site, it was stolen and republished in violation of US & international copyright legislation. The correct version of this article can be viewed at https://www.watchlistnews.com/natus-medical-incorporated-baby-position-held-by-olstein-capital-management-l-p/1495148.html.

A number of brokerages have issued reports on BABY. BidaskClub lowered Natus Medical from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Zacks Investment Research lowered Natus Medical from a “hold” rating to a “sell” rating in a research note on Friday, July 28th. Benchmark Co. reaffirmed a “buy” rating and issued a $48.00 price objective (down from $55.00) on shares of Natus Medical in a research note on Monday, May 1st. Finally, TheStreet lowered Natus Medical from a “b” rating to a “c+” rating in a research note on Thursday, April 27th. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating and one has assigned a buy rating to the company. The company has an average rating of “Hold” and an average price target of $45.00.

In other Natus Medical news, Director Doris Engibous sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, May 25th. The stock was sold at an average price of $32.68, for a total value of $163,400.00. Following the completion of the transaction, the director now owns 22,650 shares of the company’s stock, valued at approximately $740,202. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director William M. Moore sold 3,000 shares of the company’s stock in a transaction that occurred on Monday, August 14th. The shares were sold at an average price of $34.10, for a total value of $102,300.00. Following the completion of the transaction, the director now directly owns 30,410 shares of the company’s stock, valued at approximately $1,036,981. The disclosure for this sale can be found here. Corporate insiders own 5.50% of the company’s stock.

Natus Medical Company Profile

Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.

Want to see what other hedge funds are holding BABY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natus Medical Incorporated (NASDAQ:BABY).

Institutional Ownership by Quarter for Natus Medical (NASDAQ:BABY)

Receive News & Ratings for Natus Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.